Tetraphase raising $150m
This article was originally published in Scrip
Massachusetts-based antibiotic drug developer Tetraphase Pharmaceuticals is aiming to raise $150m through a public offering of 4,300,000 shares of common stock at $35 per share. The offer is expected to close on or around 17 March 2015. Tetraphase reported positive Phase III data in December last year for its lead antibiotic compound eravacycline as a treatment for complicated intra-abdominal infections. Data from a second Phase III trial in complicated urinary tract infections are expected by mid-2015. Tetraphase is aiming to file a New Drug Application to the FDA for eravacycline by the end of this year. BMO Capital Markets, Stifel and Guggenheim Securities are acting as joint bookrunning managers for the offering and Nomura and SunTrust Robinson Humphrey are acting as co-managers.
You may also be interested in...
A rush in the 2010s of high-tech and digital companies focused on women’s health and wellbeing are maturing, adding weight to the more traditional women's health market that has struggled to get attention from investors in the past.
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
A selection of articles you might have missed from September 2020, including exclusive interviews with industry leaders and a review of value-based contract approaches in the US.